Pharmexa: first patient immunized in PrimoVax trial for pancreatic cancer

By Lisa Kerner

Charlotte, N.C., July 3 - Pharmexa A/S said the first patient has been immunized with GV1001 against pancreatic cancer in the PrimoVax trial at a site in Spain.

The phase 3 trial of 520 patients at 60 centers in Europe and Australia will test GV1001 side by side with the current standard chemotherapy treatment, gemcitabine.

Based in Horsholm, Denmark, Pharmexa is focused on active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.